cycloalternan: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
cyclobis-(1->6)-alpha-nigerosyl : A cyclic tetrasaccharide constructed from four alpha-glucopyranosyl residues joined by alternate alpha-(1->6)- and alpha-(1->3)-linkages. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 11686063 |
| CHEBI ID | 136822 |
| MeSH ID | M0380150 |
| Synonym |
|---|
| cyclobis-(1->6)-alpha-nigerosyl |
| CHEBI:136822 |
| cyclobis-(1->3)-alpha-isomaltosyl |
| cyclic nigerosylnigerose |
| cyclotetraglucose [inci] |
| alpha-d-glucopyranose, o-alpha-d-glucopyranosyl-(1-3)-o-alpha-d-glucopyranosyl-(1-6)-o-alpha-d-glucopyranosyl-(1-3)-, cyclic 1,6'''-anhydride |
| ct-11 |
| cyclotetraglucose |
| 80as740c52 , |
| unii-80as740c52 |
| cycloalternan |
| 159640-28-5 |
| ins no.1504(i) |
| ins no.1504(ii) |
| .alpha.-d-glucopyranose, o-.alpha.-d-glucopyranosyl-(1-3)-o-.alpha.-d-glucopyranosyl-(1-6)-o-.alpha.-d-glucopyranosyl-(1-3)-, cyclic 1,6'''-anhydride |
| e-1504(ii) |
| ins-1504(ii) |
| cycloalternanotetraose |
| ins-1504(i) |
| cyclic nigerosyl-(1->6)-nigerose |
| cyclotetraose |
| e-1504(i) |
| DTXSID70166703 |
| C21655 |
| cyclobis-1,6-alpha-nigerosyl |
| (1r,3s,4r,5r,7s,10r,11s,12s,13r,14r,16s,17r,18r,20s,23r,24s,25s,26r,28r,30r)-5,18-bis(hydroxymethyl)-2,6,8,15,19,21,27,29-octaoxapentacyclo[21.3.1.13,7.110,14.116,20]triacontane-4,11,12,13,17,24,25,26,28,30-decol |
| Q27269133 |
| |a-d-glucopyranose, o-|a-d-glucopyranosyl-(1 inverted exclamation marku3)-o-|a-d-glucopyranosyl-(1 inverted exclamation marku6)-o-|a-d-glucopyranosyl-(1 inverted exclamation marku3)-, cyclic 1,6'''-anhydride |
| Class | Description |
|---|---|
| macrocycle | A cyclic compound containing nine or more atoms as part of the cyclic system. |
| tetrasaccharide | An oligosaccharide comprising four monomeric monosaccharide units. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| cyclobis-(1u21926)-u03B1-nigerosyl degradation | 1 | 5 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.06) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (7.69%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (92.31%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||